Rankings
▼
Calendar
REGN Q2 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q2 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.6B
-1.9% YoY
Gross Profit
$1.4B
87.5% margin
Operating Income
$316M
20.0% margin
Net Income
$193M
12.2% margin
EPS (Diluted)
$1.68
QoQ Revenue Growth
+14.9%
Cash Flow
Operating Cash Flow
$188M
Free Cash Flow
$94M
Stock-Based Comp.
$106M
Balance Sheet
Total Assets
$13.2B
Total Liabilities
$3.4B
Stockholders' Equity
$9.8B
Cash & Equivalents
$1.0B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.6B
$1.6B
-1.9%
Gross Profit
$1.4B
$1.5B
-6.9%
Operating Income
$316M
$622M
-49.3%
Net Income
$193M
$551M
-65.0%
Revenue Segments
Product
$1.2B
100%
← FY 2019
All Quarters
Q3 2019 →